Genuine Biotech Honored with "2026 Forbes China Leading Enterprise in Industry Development" Award

On Mar. 18, the "2026 Forbes China Pioneer Innovators in Industry Development Selection" was officially announced. Genuine Biotech, leveraging on its innovation performance,influence, and long-term development potential in the field of biomedicine, won the "2026 Forbes China Leading Enterprise in Industry Development" award.

The selection focused on key fields such as AI technology, consumer sector, healthcare, new energy, manufacturing industry, and service industry. Through rigorous data analysis and in-depth market research, the selection aimed to identify industry pioneers with extensive influence and an innovative spirit in China and around the world.

As a biotechnology company centered on innovative R&D, Genuine Biotech is dedicated to the R&D, manufacturing, and commercialization of innovative drugs in the fields of viral infections, neoplasms, and cerebrovascular disorders, always focusing on addressing unmet clinical needs and building unique R&D pipelines with competitive advantages.

In the field of antiviral therapeutics, Genuine Biotech has made significant efforts in the past in fighting against the COVID-19 pandemic via the independently developed Class 1.1 novel drug, Azvudine. At present, with its unique mechanism of dual-target antiviral effect and immunity enhancement, Azvudine has brought new hope for tackling the global problem of incomplete immune reconstitution in human immunodeficiency virus (HIV) treatment. Meanwhile, the R&D of CL-197 and the combination tablet of CL-197 and Azvudine is also progressing smoothly, with the potential to create the world's first all-oral long-acting treatment for HIV.

In the field of anti-tumor therapeutics, Genuine Biotech has also built innovative R&D pipelines with high synergistic effects. Azvudine in combination with PD-1 monoclonal antibody (mAb) for the treatment of solid tumors was approved for clinical trials last month, marking Genuine Biotech's attempts to explore effective solutions for the clinical predicament of the lack of response to immunotherapy in patients with microsatellite-stable (MSS) colorectal cancer.

Also, Dosimertinib, the next-generation EGFR-targeted drug developed by the Company in the field of lung cancer treatment, has entered phase II clinical trials. It has shown potential advantages in the treatment of lung cancer and brain metastases from lung cancer in preclinical studies, with an excellent safety profile and encouraging preliminary efficacy data obtained in phase I clinical trials. At present, Genuine Biotech is simultaneously advancing the clinical trial of Azvudine in combination with Dosimertinib to explore the possibility of continued benefits to patients who have progressed after third-generation EGFR-TKI treatment.

In addition, the novel-structure TOPO1 inhibitor, ZSSW-136, overcomes the resistance to camptothecin and is expected to provide an effective solution for ADC-resistant tumors.

Genuine Biotech adheres to independent innovation using core technologies, has established a mature, complete, and sustainable whole-process drug R&D system, and continues promoting the efficient transformation of innovative achievements relying on multiple featured technology platforms.

Dr. Du Jinfa, Chairman and CEO of Genuine Biotech, said that true pioneer innovators never follow trends, but create possibilities. In the future, Genuine Biotech will continue to focus on unmet clinical needs and boldly go where no man has gone before in the field of pharmaceutical innovation, offering more innovative Chinese therapies to patients worldwide.